A 12-year-old boy diagnosed with a rare degenerative muscle condition has recently commenced a transformative NHS treatment after a period of uncertainty for his family.
Ben Clarke suffers from Duchenne Muscular Dystrophy (DMD), a severe genetic disorder that predominantly affects boys, leading to muscle deterioration over time. He is one of numerous patients to receive givinostat, following its approval for use in select NHS Trusts through an early access initiative.
Despite the positive news, Ben’s father, Alex Clarke, emphasized the ongoing battle, expressing concern that other families might lose their sons before gaining access to the same treatment. Alex described Ben’s joy upon learning of the drug’s approval, noting the absence of adverse effects and Ben’s improved well-being.
Givinostat aims to slow the disease’s progression and maintain muscle function, albeit it is exclusively sanctioned for ambulant boys.
While the approval marks a milestone for Ben’s family, Alex emphasized that the campaign continues, citing the drug’s limitation to ambulant boys.
Ben received his DMD diagnosis at the age of four in 2017, prompting his family’s quest for further information and treatment options after noticing concerning symptoms.
Reflecting on the initial diagnosis, Alex mentioned the misinformation they encountered online, which suggested a bleak future for Ben, causing immense distress and uncertainty.
Now 12 years old, Ben, who attends a mainstream school, exudes positivity and brightness, according to his father.
While Ben can still walk, he increasingly relies on a wheelchair for longer distances, with everyday tasks becoming more challenging for him.
After over a year of advocacy alongside Duchenne UK through the ‘Time is Muscle’ campaign, the Clarke family finally secured access to givinostat, despite initial obstacles in Ben’s trust.
Highlighting the delays in accessing the medication, Alex stressed the need for a more efficient process to ensure timely treatment for affected children.
He urged for broader access to givinostat, particularly for non-ambulant individuals, emphasizing the urgency to prevent further setbacks and disparities.
Addressing the disparity in access to treatments, Alex emphasized the critical need to expedite the process to benefit all affected individuals, regardless of their location or circumstances.